Oehler Daniel, Böttger Charlotte, Immohr Moritz Benjamin, Bruno Raphael Romano, Haschemi Jafer, Scheiber Daniel, Horn Patrick, Aubin Hug, Tudorache Igor, Westenfeld Ralf, Akhyari Payam, Kelm Malte, Lichtenberg Artur, Boeken Udo
Division of Cardiology, Pulmonology and Vascular Medicine Medical Faculty, Heinrich-Heine University, 40225 Düsseldorf, Germany.
Department of Diagnostic and Interventional Radiology, Medical Faculty, Heinrich-Heine University, 40225 Düsseldorf, Germany.
Life (Basel). 2022 Jul 14;12(7):1053. doi: 10.3390/life12071053.
Prolonged treatment of organ donors in the intensive care unit (ICU) may be associated with complications influencing the outcome after heart transplantation (HTx). We therefore aim to explore the potential impact of the donor length of stay (LOS) in the ICU on outcomes in our cohort. We included all patients undergoing HTx in our center between September 2010 and April 2022 ( = 241). Recipients were divided around the median into three groups regarding their donor LOS in the ICU: 0 to 3 days (≤50th percentile, = 92), 4 to 7 days (50th-75th percentile, = 80), and ≥8 days (≥75th percentile, = 69). Donor LOS in the ICU ranged between 0 and 155 days (median 4, IQR 3-8 days). No association between the LOS in the ICU and survival after HTx was observed (AUC for overall survival 0.514). Neither the Kaplan-Meier survival analysis up to 5 years after HTx (Log-Rank = 0.789) nor group comparisons showed significant differences. Baseline recipient characteristics were comparable between the groups, while the donor baselines differed in some parameters, such as less cardiopulmonary resuscitation prior to HTx in those with a prolonged LOS. However, regarding the recipients' peri- and postoperative parameters, the groups did not differ in all of the assessed parameters. Thus, in this retrospective analysis, although the donors differed in baseline parameters, the donor LOS in the ICU was not associated with altered recipient survival or outcome after HTx.
在重症监护病房（ICU）对器官捐献者进行长时间治疗可能会出现一些并发症，影响心脏移植（HTx）后的结果。因此，我们旨在探讨捐献者在ICU的住院时间（LOS）对我们队列中患者结局的潜在影响。我们纳入了2010年9月至2022年4月期间在我们中心接受HTx的所有患者（n = 241）。根据捐献者在ICU的LOS中位数，将接受者分为三组：0至3天（≤第50百分位数，n = 92）、4至7天（第50 - 75百分位数，n = 80）和≥8天（≥第75百分位数，n = 69）。捐献者在ICU的LOS在0至155天之间（中位数4天，四分位间距3 - 8天）。未观察到ICU住院时间与HTx后生存率之间存在关联（总生存率的AUC为0.514）。HTx后长达5年的Kaplan-Meier生存分析（对数秩检验P = 0.789）以及组间比较均未显示出显著差异。组间接受者的基线特征具有可比性，而捐献者的基线在一些参数上有所不同，例如LOS延长的患者在HTx前接受心肺复苏的次数较少。然而，就接受者的围手术期和术后参数而言，各组在所有评估参数上并无差异。因此，在这项回顾性分析中，尽管捐献者的基线参数存在差异，但捐献者在ICU的LOS与HTx后接受者生存率的改变或结局并无关联。
